Literature DB >> 8375580

Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM?

D L Eizirik1, S Sandler, J P Palmer.   

Abstract

Most studies dealing with the pathogenesis of IDDM have emphasized the immune assault against beta-cells. In this perspective, we review the data that suggest that the beta-cell destruction of IDDM depends on a balance between beta-cell damage and repair. The progressive beta-cell damage leading to IDDM seems to follow markedly different temporal courses in individual patients. Some individuals at high risk for developing IDDM, and presenting with impaired beta-cell function, appear to recover beta-cell function when followed prospectively. Moreover, after the clinical onset of IDDM, most patients experience a transitory period of improved insulin secretion. In vitro and in vivo experimental data suggest that beta-cells are indeed able to repair themselves after damage. Dispersed beta-cells or whole islets can survive and regain their function after a toxic assault. Furthermore, the abnormal insulin release and glucose oxidation of islets isolated from NOD mice during the prediabetic period is completely restored after 1 wk in tissue culture. Finally, treatment of NOD mice with monoclonal antibodies directed against infiltrating T-cells reverses the altered glucose metabolism of beta-cells. Note that beta-cell repair after exposure to different toxic agents can be enhanced both in vivo and in vitro. Potential enhancers of beta-cell repair are nicotinamide, glucose, protein-rich diets, and branched chain amino acids. A basic question that remains to be answered is the nature of the repair mechanisms triggered by beta-cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375580     DOI: 10.2337/diab.42.10.1383

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

1.  Cytokines suppress human islet function irrespective of their effects on nitric oxide generation.

Authors:  D L Eizirik; S Sandler; N Welsh; M Cetkovic-Cvrlje; A Nieman; D A Geller; D G Pipeleers; K Bendtzen; C Hellerström
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

2.  Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes.

Authors:  Yi-Chun Chen; E Scott Colvin; Katherine E Griffin; Bernhard F Maier; Patrick T Fueger
Journal:  Diabetologia       Date:  2014-07-04       Impact factor: 10.122

3.  N-monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets.

Authors:  F J Bedoya; F Solano; M Lucas
Journal:  Experientia       Date:  1996-04-15

4.  Preventing insulin dependent diabetes mellitus.

Authors:  K G Alberti
Journal:  BMJ       Date:  1993-12-04

5.  Transgenic mice expressing Shb adaptor protein under the control of rat insulin promoter exhibit altered viability of pancreatic islet cells.

Authors:  M Welsh; L Christmansson; T Karlsson; S Sandler; N Welsh
Journal:  Mol Med       Date:  1999-03       Impact factor: 6.354

Review 6.  The role of inflammation in insulitis and beta-cell loss in type 1 diabetes.

Authors:  Décio L Eizirik; Maikel L Colli; Fernanda Ortis
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

Review 7.  The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells.

Authors:  D L Eizirik; M Flodström; A E Karlsen; N Welsh
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

8.  Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury.

Authors:  D L Eizirik; D G Pipeleers; Z Ling; N Welsh; C Hellerström; A Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

9.  Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus.

Authors:  N Welsh; B Margulis; L A Borg; H J Wiklund; J Saldeen; M Flodström; M A Mello; A Andersson; D G Pipeleers; C Hellerström
Journal:  Mol Med       Date:  1995-11       Impact factor: 6.354

10.  Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone.

Authors:  Rodrigo N Lamounier; Cassio N Coimbra; Peter White; Flavia L Costal; Leonardo S Oliveira; Daniel Giannella-Neto; Klaus H Kaestner; Maria Lúcia Corrêa-Giannella
Journal:  Diabetol Metab Syndr       Date:  2013-01-08       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.